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The previous version of this article contained some errors, which have now been corrected in all subsequent versions. The errors in the previous version were as follows:

In Figure 1, the table accompanying the graph in Figure 1C incorrectly mentioned 'Afatinib' instead of 'Osimertinib'. This has now been corrected.Reference 22 was incorrectly cited at the end of the following sentence on page 2: 'Although they were associated with a class-related safety profile with characteristic adverse events (AEs), including gastrointestinal (e.g. diarrhea, stomatitis) and cutaneous (e.g. rash/acne) events, they were better tolerated than chemotherapy.' This citation has now been removed.On page 5, in the paragraph 'Osimertinib versus erlotinib/gefitinib: FLAURA', the hazard ratio and p-value for progression-free survival were incorrectly reported, and some of the information regarding the most frequent adverse events was inaccurate. These errors have now been corrected.In Figure 2, some of the data regarding progression-free survival ranges and mutation rates, as well as the supporting references, were incorrectly reported. The figure has now been corrected.

The authors would like to apologise for these errors.
